|Mr. Gregory P. Madison||Chief Exec. Officer, Pres and Director||783.07k||N/A||49|
|Mr. Scott A. Holmes M.S., M.B.A., CPA||Chief Financial Officer, Sr. VP and Treasurer||494.47k||N/A||43|
|Mr. Brian R. Adams||Sr. VP, Gen. Counsel and Sec.||485.79k||N/A||43|
|Dr. John F. Neylan M.D.||Chief Medical Officer and Sr. VP||568.83k||N/A||64|
|Ms. Christine A. Carberry CSAP||Chief Operating Officer and Sr. VP||N/A||N/A||56|
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has a license agreement with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Keryx Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 5; Compensation: 8.